LEO Pharma strengthens global leadership team
30.6.2020 12:43:59 CEST | LEO Pharma | Press release
The company has set out on an ambitious growth journey to become a leading provider of innovative medicines helping patients with skin diseases. To align with its strategic objectives, it re-organizes its executive leadership team.
Dr. Monica Shaw, M.D., will assume the position of Executive Vice President, Region Europe+, effective July 1, 2020. Shaw joins LEO Pharma from GSK/ViiV Healthcare in Singapore, where she was VP Commercial, Head Asia Pacific region. She is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams and an extensive specialty experience within the pharmaceutical industry including in dermatology, immuno-inflammation and rare diseases. She has held several leadership positions internationally in Europe, Asia and Latin America.
“Monica Shaw’s experience in biologics, dermatology and specialty pharma will help us to be successful in our move to launch innovative treatments and become a global leader in medical dermatology. Her combination of global experience, great leadership skills and clinical background will contribute significantly to reach our ambitions,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Nathalie Joannes will join LEO Pharma as Executive Vice President, Legal and Compliance and General Counsel from September 1, 2020. She joins LEO Pharma from Roquette Freres’ headquarters in Paris, where she has been Group General Counsel. During Joannes’ long-standing career as general counsel in the life-sciences and pharmaceutical industries, she successfully built international teams in legal, risk management and compliance in publicly traded and privately owned, global companies. She holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar.
“Nathalie Joannes has a proven track record in counseling global companies and her global pharma and life-science industry experience will be of great value for LEO Pharma on its way to become a leading provider of innovative medicines. She is a highly experienced lawyer and builder of strong international teams, which will help us immensely,” said Mazzacco.
Effective July 1, 2020, Guillaume Clemént, currently Executive Vice President, Region Europe+, will assume responsibility for Region International and the thrombosis business, after having successfully led Region Europe+ in the last four years.
Official bios
Monica Shaw
Dr. Monica Shaw, M.D., is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams to deliver business performance and successful drug development. Monica Shaw has extensive specialty experience within the pharma industry working within dermatology, immuno-inflammation, HIV, neurology and oncology. She has held several leadership positions in the global pharma industry located in i.e. Europe, Asia and Latin America.
Monica Shaw earned an M.D. M.A. and is a Member of the Royal College of Physicians.
Employment History
VP Commercial Head Asia Pacific region, GSK/ViiV Healthcare
2018 to current
General Manager, GlaxoSmithKline
2016 – 2018
VP Global Franchise Medical Head for Specialty, GlaxoSmithKline
2014 – 2016
UK Chief Scientific Officer, Novartis
2013 – 2014
Global Therapy Area Director for Clinical Development and Business Development, Norgine
2011 – 2013
Global Clinical Director ADHD, Shire
2009 – 2011
Nathalie Joannes
Nathalie Joannes holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar since 1987. During her long-standing career as general counsel in the chemical and pharmaceutical industries, she successfully built international teams and guided listed pharma companies through the legal aspects of mergers & acquisitions, partnerships, high-risk litigations, anti-trust investigations, corporate governance and compliance.
Employment History
Group General Counsel, Roquette Frères
2016 to current
EVP and Group General Counsel, IPSEN
2011 – 2015
SVP and Chief European Counsel, Genzyme
2008 – 2011
General Counsel International, Cardinal Health
2007 – 2008
Group General Counsel, Serono International
2001 – 2007
Contacts
Henrik Kyndlev
+45 3140 6180
HDTDK@LEO-Pharma.com
Images
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information please visit: www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis9.7.2026 17:00:00 CEST | Pressemeddelelse
TRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Tralokinumab was generally well tolerated for up to 172 weeks of treatment, with no new safety signals identified.
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen25.6.2026 13:00:00 CEST | Pressemeddelelse
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi8.6.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma has achieved Science Based Targets initiative (SBTi) validation for its net-zero climate targets, including its ambition to reach net-zero greenhouse gas emissions by 2050, alongside near-term goals to reduce Scope 1 and 2 emissions by 63% and Scope 3 emissions by 37.5% by 2035 With its targets now validated, LEO Pharma is shifting from target-setting to implementation, advancing 15 prioritized initiatives in its Climate Transition Plan while emphasizing the connection between environmental health and patient care
LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse
LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline5.5.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio. LEO Pharma also made significant strategic progress and advanced innovation through the acquisition of Replay’s next-generation gene therapy platform targeting rare genetic skin diseases, the approval of Enstilar® in China and the continued late-stage development activities for Anzupgo®, including FDA acceptance for review in adolescents with chronic hand eczema. Financial highlights LEO Pharma’s revenue increased by 4% to DKK 3,521 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (30% at CER) and Rest of World (13% at CER), whereas sales in Europe declined by 1% at CER. Revenue from the dermatology portfolio grew by 11% (CER), driven by the strat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom